Advertisement
Advertisement
U.S. Markets close in 3 hrs 24 mins
Advertisement
Advertisement
Advertisement
Advertisement

Evaxion Biotech A/S (EVAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.6599+0.0499 (+3.10%)
As of 12:27PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.6100
Open1.6100
Bid1.6300 x 1100
Ask1.6600 x 1000
Day's Range1.6100 - 1.6784
52 Week Range1.4100 - 3.5200
Volume126,938
Avg. Volume319,105
Market Cap38.413M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • MarketWatch

    Evaxion's stock soars after getting FDA approval for mid-stage cancer trial

    U.S.-listed shares of Evaxion Biotech A/S jumped about 17% in premarket trading on Tuesday after the company said the Food and Drug Administration has allowed a Phase 2b clinical trial testing its experimental cancer vaccine to move forward. The study is evaluating Evaxion's EVX-01 in combination with Merck & Co. Inc.'s Keytruda as a treatment for metastatic melanoma in Australia, Europe, and the U.S. Erik Heegaard, Evaxion's chief medical officer, said the FDA's decision "is an important step t

  • Benzinga

    Evaxion, ExpreS2ion Ink Research Pact For Cytomegalovirus Vaccine Candidate

    Evaxion Biotech A/S (NASDAQ: EVAX) has signed a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech Holding AB for the joint development of a novel cytomegalovirus (CMV) vaccine candidate. During the discovery phase of the collaboration, Evaxion will use its proprietary AI platform, RAVEN, to design a next-generation vaccine candidate that elicits both cellular and humoral/antibody responses. The antigen constructs derived from Evaxion's AI platform will be produced by ExpreS2ion,

  • Benzinga

    Evaxion Biotech Highlights Promising Data From Personalized Cancer Immunotherapy

    Evaxion Biotech A/S (NASDAQ: EVAX) has announced interim safety and immunogenicity data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02. In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and targets cancer mutations, neoantigens, in patients with resected melanoma. "We are thrilled to announce promising interim data from the first eight patients...All patients demonstrated a specific T-cell immune response induced by the trea

Advertisement
Advertisement